IONIS PHARMACEUTICALS INC (IONS) Stock Price & Overview
NASDAQ:IONS • US4622221004
The current stock price of IONS is 74.79 USD. Today IONS is down by -1.15%. In the past month the price decreased by -11.27%. In the past year, price increased by 126.91%.
IONS Key Statistics
- Market Cap
- 12.355B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.44
- Dividend Yield
- N/A
IONS Stock Performance
IONS Stock Chart
IONS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IONS. When comparing the yearly performance of all stocks, IONS is one of the better performing stocks in the market, outperforming 93.35% of all stocks.
IONS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IONS. IONS has a bad profitability rating. Also its financial health evaluation is rather negative.
IONS Earnings
On February 25, 2026 IONS reported an EPS of -1.41 and a revenue of 203.00M. The company missed EPS expectations (-4.63% surprise) and beat revenue expectations (27.5% surprise).
IONS Forecast & Estimates
29 analysts have analysed IONS and the average price target is 92.16 USD. This implies a price increase of 23.23% is expected in the next year compared to the current price of 74.79.
For the next year, analysts expect an EPS growth of -58.89% and a revenue growth -6.89% for IONS
IONS Groups
Sector & Classification
IONS Financial Highlights
Over the last trailing twelve months IONS reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS increased by 19.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.82% | ||
| ROE | -77.98% | ||
| Debt/Equity | 3.88 |
IONS Ownership
IONS Latest News, Press Relases and Analysis
IONS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 401.392B | ||
| AMGN | AMGEN INC | 16.55 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.52 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.57 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.95 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.85 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.18 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IONS
Company Profile
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Company Info
IPO: 1991-05-17
IONIS PHARMACEUTICALS INC
2855 Gazelle Court
Carlsbad CALIFORNIA 92010 US
CEO: Brett P. MONIA
Employees: 1402
Phone: 17609319200
IONIS PHARMACEUTICALS INC / IONS FAQ
What does IONS do?
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
What is the stock price of IONIS PHARMACEUTICALS INC today?
The current stock price of IONS is 74.79 USD. The price decreased by -1.15% in the last trading session.
Does IONS stock pay dividends?
IONS does not pay a dividend.
How is the ChartMill rating for IONIS PHARMACEUTICALS INC?
IONS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is IONIS PHARMACEUTICALS INC (IONS) stock traded?
IONS stock is listed on the Nasdaq exchange.
What is the expected growth for IONS stock?
The Revenue of IONIS PHARMACEUTICALS INC (IONS) is expected to decline by -6.89% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.